Brain Biotech Ag · XETR:BNN
Brain Biotech — Deutsches Eigenkapitalforum 2024
20 slides from Brain Biotech's conference presentation, Nov 25, 2024
Slide 1: BRAIN Biotech AG - Creating a #BiobasedFuture
BRAIN Biotech AG Creating a #BiobasedFuture Deutsches Eigenkapitalforum 2024 Adriaan Moelker, CEO November, 25th 2024 Since 2021 we have been committed to the UN Global Compact corporate responsibility initiative and its principles in the areas of human rights, labor, the environment and anti-corrup
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assum
Slide 3: Who is BRAIN Biotech?
Who is BRAIN Biotech? investing in the century of the bioeconomy ~ € 55.3m ~ 600 ~ 310 Revenues Specialty products for B2B Employees € € 402,000 40 > 30 Active patent families with varying Adjusted EBITDA Years of Experience numbers of individual patents 32 % ~ 200 2016 Equity ratio Industrial Partn
Slide 4: Why does Biotech matter to you?
Why does Biotech matter to you? sustainability through biotechnology Climate change & exceeding the earth's limits Nature is our role model for solving complex problems Comprehensive technology package: valuable for various fields of application & markets We have the methods & skills to seriously co
Slide 5: #BRAINimpact: Projects and enabling Technologies
#BRAINimpact: Projects and enabling Technologies solutions provider for the megatrends, sustainability embedded Food enzymes (beverage Life Science solutions Starch processing Dairy replacing proteins High-yield industrial Baking, Dairy) Enzymes Production microbes Novel sweetener Natural preservati
Slide 6: BRAIN Biotech as a solutions provider across the value chain
BRAIN Biotech as a solutions provider across the value chain integrated solutions for customers Sales Formulation and Blending Production in industrial scale Bioprocess development Strain development Expression technology Microbial strains Discovery Protein Engineering Rational selection BioProducts
Slide 7: Enabling Bio-Process Driven Production
Enabling Bio-Process Driven Production from design to industrial scale production Process design & development Scale up • Process simulation • Fermentation: 70 L – 750 L • Fermentation: 1 L – 200 L • DSP scale up Industrial production Downstream processing (DSP) • Product purification • Fermentation
Slide 8: MetXtra – Find Your Unique Enzyme
MetXtra – Find Your Unique Enzyme over 30 years of experience combined with Bioinformatics, Machine Learning & AI MetXtra™ Suite ► BRAIN Biotech’s Enzyme Discovery Technology MetXtra™ db ► Proprietary sequence database (99.8% novelty) MetXtra™ ai ► AI predictions for enzyme selection MetXtra™ sb ► S
Slide 9: Efficient & transparent Organization
Efficient & transparent Organization aligning external reporting with business accountability Biotech AG BioProducts BioScience BioIncubator Enzyme products, microorganisms & R&D services for Projects & participations ingredients tailor-made solutions to create innovative solutions Incubator Biotech
Slide 10: Efficient & transparent Organization: BRAIN Biotech AG Holding
Efficient & transparent Organization gaining financial flexibility via strategic reorganization • Active portfolio management • Facilitate cross-divisional synergies BRAIN Biotech AG “Holding” • Drive M&A • Equity financing for strategic considerations BioProducts BioScience BioIncubator • Further i
Slide 11: Business Highlights 9M FY 2023/24: BioProducts
Business Highlights 9M FY 2023/24: BioProducts stable YoY but with excellent starting positions for future growth BioProducts Baking Enzymes on a strong growth path Beverages and Starch processing enzymes back to growth after turn-around Food specialities and Fermentation very strong EBITDA
Slide 12: Business Highlights 9M FY 2023/24: BioScience
Business Highlights 9M FY 2023/24: BioScience strong project pipeline for 2024/25 Pharvaris/Royalty Pharma deal concluded: Up to €129m + €9m = €138m potential cash Tailor Made Solutions: Tougher market conditions as budgets are reduced Akribion Therapeutics: Venture Capital Consortium engaged
Slide 13: Financial Highlights 9M FY 2023/24 at a Glance
Financial Highlights 9M FY 2023/24 at a Glance major milestone income in BioIncubator –BioScience with weakening momentum since Q1 9M 9M Organic Q3 Q3 Organic Comment Growth Growth (in € thousand) 2023/24 2022/23 Growth 2023/24 2022/23 Growth Revenues 40,394 40,393 0.0% 0.0% 13,190 13,223 -0.2% -0.2
Slide 14: Cash & Cash Flow
Cash & Cash Flow cash position significantly strengthened; all financing measures successfully executed 9M 9M Q3 Q3 Comment Growth Growth (in € thousand) 2023/24 2022/23 2023/24 2022/23 Gross Cash Flow -6,179 -4,026 -53.5% -1,809 -1,228 -47.3% Operating Cash Flow -2,670 -4,480 40.4% 516 1,078 -52.1%
Slide 15: Our Targets
Our Targets FY Guidance and Mid-Term Targets Updated FY Guidance: lower end of initial sales Mid-Term Targets - Unchanged guidance (issued 02/23; 4-6 year targets) (excluding Akribion Genomics) Quantitative Guidance Group sales: € 58 to 62 million € 100 million group revenues BioProducts and BioSc
Slide 16: Profitable sales growth is our objective
Profitable sales growth is our objective strong positive trend in our key performance indicators revenue & adjusted EBITDA 60.000 60,000 1.000 1,000 55.335 49.509 500 500 50.000 50,000 402 38.389 - 40.000 40,000 -98 adjusted EBITDA -500 -500 Revenue 30.000 30,000 -1.000 -1,000 20.000 20,000 -1.500 -
Slide 17: Why invest in BRAIN Biotech?
Why invest in BRAIN Biotech? Five strong reasons 1. Clear strategy of profitable growth Our goal is to be one of the world’s top 10 enzyme companies. 2. Significant market opportunities We have excellent market opportunities in our growth areas food, life sciences and environment. 3. Growing demand
Slide 18: BRAIN Biotech CMD – December 12th in Zwingenberg
BRAIN Biotech CMD – December 12th in Zwingenberg with an additional live stream Planned Agenda: 1. BRAIN Biotech Group strategy and priorities. Our unique customer offering and 5-year outlook Adriaan Moelker, CEO 2. BRAIN-Biocatalysts’ unique technology and production platforms Andrew Ellis, VP Ferm
Slide 19: Our analyst ratings
Our analyst ratings BioProducts and BioIncubator as value drivers Bank Analyst Price Target Recommendation Konstantin Wiechert / 5.20 € Buy Thomas Meyer Jan Koch 10.00 € Buy Dr. Mohamad Vaseghi 6.50 € Buy Nicolas Pauillac 7.70 € Buy Dr. Christian Ehmann 5.90 € Buy Creating a #BiobasedFuture © BRAIN
Slide 20: Thank you very much for your interest.
Thank you very much for your interest. BRAIN Biotech AG Darmstädter Straße 34−36 64673 Zwingenberg, Germany +49 (0) 6251-9331-0 www.brain-biotech-group.com Your contacts: Adriaan Moelker, CEO Michael Schneiders, CFO Martina Schuster, IR +49 (0) 6251-9331-69 [email protected] brainbiotechag BRAIN